Apontis Pharma AG/€APPH
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Apontis Pharma AG
Apontis Pharma AG operates in the pharmaceutical industry, focusing on the development and commercialization of single pill combinations (SPCs) designed for cardiovascular diseases, diabetes, and other conditions. Headquartered in Monheim am Rhein, Germany, the company leverages its expertise to simplify patient therapy regimens, aiming to improve adherence and outcomes. Apontis Pharma's offerings revolve around combining multiple active ingredients into a single dosage form, which can enhance patient convenience and compliance. Its strategic emphasis on SPCs caters to an increasing demand for streamlined pharmacological treatments, particularly in the management of chronic illnesses. Apontis Pharma's competitive strength lies in its unique focus on SPCs, underpinned by an experienced management team and a robust distribution network within Germany.
Ticker
€APPH
Sector
Primary listing
XETRA
Industry
Pharmaceuticals
Headquarters
Employees
137
ISIN
DE000A3CMGM5
Website
APPH Metrics
BasicAdvanced
€90M
120.49
€0.09
1.24
-
Price and volume
Market cap
€90M
Beta
1.24
52-week high
€12.35
52-week low
€6.30
Average daily volume
1.6K
Financial strength
Current ratio
2.486
Quick ratio
1.702
Interest coverage (TTM)
10.39%
Profitability
EBITDA (TTM)
3.434
Gross margin (TTM)
57.16%
Net profit margin (TTM)
1.55%
Operating margin (TTM)
2.46%
Effective tax rate (TTM)
33.04%
Revenue per employee (TTM)
€350,000
Management effectiveness
Return on assets (TTM)
1.47%
Return on equity (TTM)
2.46%
Valuation
Price to earnings (TTM)
120.49
Price to revenue (TTM)
1.873
Price to book
2.91
Price to tangible book (TTM)
4.77
Price to free cash flow (TTM)
-17.323
Free cash flow yield (TTM)
-5.77%
Free cash flow per share (TTM)
-62.92%
Growth
Revenue change (TTM)
31.12%
Earnings per share change (TTM)
-106.67%
3-year revenue growth (CAGR)
-1.80%
3-year earnings per share growth (CAGR)
1.05%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Apontis Pharma AG stock?
Apontis Pharma AG (APPH) has a market cap of €90M as of July 04, 2025.
What is the P/E ratio for Apontis Pharma AG stock?
The price to earnings (P/E) ratio for Apontis Pharma AG (APPH) stock is 120.49 as of July 04, 2025.
Does Apontis Pharma AG stock pay dividends?
No, Apontis Pharma AG (APPH) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Apontis Pharma AG dividend payment date?
Apontis Pharma AG (APPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Apontis Pharma AG?
Apontis Pharma AG (APPH) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.